[HTML][HTML] Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic …
JE Cortes, M Baccarani, F Guilhot… - Journal of Clinical …, 2010 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2010•ncbi.nlm.nih.gov
Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in
Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic
Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity
Study - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage
MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text Archive Search in
PMC Advanced Search User Guide Journal List J Clin Oncol PMC4979244 Other Formats PDF …
Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic
Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity
Study - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage
MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text Archive Search in
PMC Advanced Search User Guide Journal List J Clin Oncol PMC4979244 Other Formats PDF …
Abstract
Purpose
To evaluate the safety and efficacy of initial treatment with imatinib mesylate 800 mg/d (400 mg twice daily) versus 400 mg/d in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
ncbi.nlm.nih.gov
